emerg
novel
influenza
pandem
viru
significantli
affect
util
healthcar
resourc
increas
morbid
mortal
children
young
adult
april
septemb
fallwint
southern
hemispher
brazil
experienc
first
wave
viru
end
decemb
death
report
brazil
emerg
data
clinic
cours
sever
infect
allow
identif
highrisk
group
includ
pregnant
women
patient
morbid
obes
howev
analysi
impact
novel
viru
highli
suscept
popul
cancer
patient
clinic
virolog
perspect
need
highlight
atyp
clinic
present
influenza
infect
cancer
patient
delay
clinic
suspicion
antivir
treatment
adequ
prevent
viral
transmiss
major
challeng
clinic
manag
popul
cancer
patient
like
suffer
sever
season
influenza
infect
prolong
viral
shed
report
season
viru
prolong
shed
develop
oseltamivir
resist
cancer
patient
infect
viru
thoroughli
evalu
data
aspect
could
major
implic
clinic
manag
infect
control
practic
cancer
patient
analysi
novel
viral
infect
cancer
patient
import
compon
pandem
conduct
prospect
cohort
studi
aim
evalu
clinic
cours
influenza
infect
durat
viral
shed
evolut
emerg
antivir
resist
hospit
cancer
patient
sever
infect
refer
cancer
center
winter
brazil
studi
period
hospit
cancer
patient
suspect
influenza
infect
screen
confirm
influenza
diagnosi
use
rapid
indirect
immunofluoresc
ifi
test
world
health
organ
recommend
realtim
rtpcr
rrtpcr
figur
tabl
among
patient
confirm
posit
viru
use
rrtpcr
figur
tabl
remain
four
patient
posit
influenza
use
ifi
consid
pandem
case
definit
refer
intern
guidelin
last
four
case
categor
case
altogeth
case
constitut
studi
popul
respiratori
sampl
collect
rrtpcrconfirm
patient
inocul
cell
cultur
recov
viru
individu
least
two
passag
mdck
constitut
isol
sampl
isol
also
analyz
oseltamivir
resist
use
function
assay
patient
diagnos
young
median
age
rang
year
total
year
old
less
year
old
hematolog
cancer
occur
patient
wherea
solid
tumor
occur
patient
tabl
total
patient
receiv
immunosuppress
therapi
previou
day
among
individu
patient
chemotherapi
receiv
system
corticosteroid
receiv
radiat
therapi
tabl
patient
receiv
erythropoietin
epo
immunomodulatori
agent
total
patient
present
febril
neutropenia
time
diagnos
median
durat
neutropenia
onset
viral
diseas
two
day
rang
one
six
day
tabl
accord
brazilian
nation
cancer
institut
protocol
patient
present
neutropenia
receiv
gcsf
normal
neutrophil
count
clinic
characterist
comparison
among
group
shown
tabl
tabl
overal
mortal
cohort
around
n
four
patient
n
least
one
comorbid
besid
cancer
patient
comorbid
one
die
pregnant
morbidli
obes
patient
identifi
total
patient
treat
oseltamivir
median
time
initi
symptom
initi
therapi
three
day
day
tabl
one
patient
die
due
sever
acut
respiratori
failur
h
clinic
suspicion
infect
never
receiv
antivir
treatment
oseltamivir
use
median
seven
day
day
doubl
dose
mg
bid
adult
twice
recommend
dose
per
kg
children
administ
patient
tabl
total
patient
receiv
oseltamivir
seven
day
six
patient
receiv
antivir
within
h
clinic
suspicion
patient
die
receiv
oseltamivir
h
onset
ill
howev
compar
mortal
patient
receiv
oseltamivir
either
within
h
onset
ill
signific
differ
observ
vs
p
differ
prolong
viral
shed
observ
two
group
present
patient
treat
broadspectrum
intraven
antimicrobi
agent
combat
communityacquir
pneumonia
andor
febril
neutropenia
five
concomit
posit
cultur
tabl
hypoxemia
frequent
median
first
arteri
blood
ga
evalu
mmhg
rang
mmhg
overal
patient
five
adult
eight
children
admit
icu
six
patient
directli
admit
emerg
depart
seven
patient
transfer
hospit
ward
tabl
ventilatori
support
given
patient
tabl
invas
mechan
ventil
perform
patient
non
invas
ventil
niv
perform
patient
tabl
among
niv
patient
one
requir
subsequ
endotrach
intub
mechan
ventil
three
patient
discharg
hospit
extrapulmonari
organ
failur
occur
eight
patient
tabl
critic
ill
patient
treat
oseltamivir
treatment
initi
h
first
signssymptom
viral
infect
adjunct
nonconvent
support
therapi
ard
perform
patient
enter
icu
total
patient
receiv
system
corticosteroid
eight
due
previou
use
two
shock
persist
ard
five
ventil
prone
posit
four
requir
recruit
maneuv
patient
receiv
extracorpor
membran
oxygen
although
prolong
influenza
shed
observ
cancer
patient
infect
season
viru
detail
data
secret
sever
ill
cancer
patient
requir
evalu
viral
shed
mechan
ventil
patient
collect
sequenti
respiratori
sampl
differ
timepoint
onset
ill
durat
viral
shed
consid
time
frame
initi
symptom
last
sampl
five
patient
group
show
viral
shed
least
day
oseltamivir
treatment
figur
tabl
median
durat
shed
day
rang
day
figur
tabl
importantli
maximum
durat
shed
investig
day
follow
day
anoth
patient
knowledg
period
constitut
longest
regist
case
shed
describ
date
rrtpcrposit
sampl
patient
longest
viral
shed
durat
cultur
mean
infecti
virus
figur
tabl
addit
last
sampl
patient
detect
use
cell
cultur
assay
suggest
presenc
low
viral
load
specimen
figur
tabl
patient
still
shed
viru
addit
day
cessat
antivir
treatment
figur
date
signific
variat
detect
amino
acid
level
hemagglutinin
ha
pandem
viru
therefor
examin
genet
divers
viru
recov
sever
ill
patient
perform
sequenc
analysi
viral
ha
gene
signific
diverg
found
isol
collect
onset
ill
four
patient
prolong
shed
figur
evalu
genet
characterist
isol
patient
prolong
viral
shed
sequenc
two
consecut
sampl
singl
individu
compar
ha
sequenc
virus
mild
sever
fatal
case
differ
countri
observ
sampl
collect
month
apart
cluster
togeth
display
rel
larg
branch
length
virus
figur
result
may
occur
strain
diverg
amino
acid
residu
number
addit
isol
sequenc
amino
acid
residu
also
mutat
fix
viral
popul
month
initi
sampl
isol
anoth
mutat
also
acquir
suggest
continu
viral
evolut
although
determin
role
mutat
viral
pathogenesi
result
alon
retent
chang
residu
time
strongli
suggest
viral
persist
rather
reinfect
consid
influenza
resist
antivir
like
emerg
immunocompromis
individu
respect
viru
studi
detect
oseltamivir
resist
investig
emerg
antivir
resist
sampl
isol
cell
cultur
thu
oseltamivir
carboxyl
valu
measur
sampl
isol
patient
found
isol
sensit
nm
display
high
valu
antivir
use
nm
sampl
sent
collabor
center
cdc
atlanta
resist
confirm
found
isol
high
valu
endow
neuraminidas
na
activ
crossresist
oseltamivir
zanamivir
peramivir
suggest
presenc
copathogen
endow
na
activ
within
isol
coinfect
respiratori
virus
coronaviru
parainfluenza
human
metapneumoviru
parechoviru
rhinoviru
rsv
ab
adenoviru
enteroviru
atyp
bacteria
mycobacterium
pneumonia
identifi
sampl
suggest
viral
sourc
na
activ
respons
high
valu
howev
coisol
streptococcu
sp
sampl
high
valu
na
activ
bacteri
strain
display
phenotyp
resist
nai
test
bacteriafre
isol
viru
consist
sensit
isol
pyrosequenc
analys
also
perform
reveal
sampl
wt
residu
thu
contain
oseltamivir
resist
marker
virus
isol
initi
onset
ill
virus
figur
prolong
influenza
shed
cancer
patient
observ
season
strain
regard
viru
shown
prolong
viru
shed
cancer
patient
may
occur
although
phenomenon
document
case
involv
singl
studi
patient
prospect
systemat
collect
inform
cohort
hospit
cancer
patient
sever
infect
patient
present
high
mortal
prolong
viral
shed
evolut
without
emerg
oseltamivir
resist
first
studi
address
viral
shed
resist
cancer
patient
infect
thu
may
provid
insight
role
cancer
patient
potenti
human
reservoir
pandem
viru
unlik
previou
report
popul
compos
hospit
sever
immunocompromis
cancer
patient
young
hematolog
malign
receiv
chemotherapi
system
steroid
week
preced
infect
patient
treat
oseltamivir
earli
cours
infect
median
time
antivir
initi
three
day
total
patient
requir
intens
care
present
sever
respiratori
distress
patient
mortal
rate
higher
observ
gener
icu
patient
suffer
infect
well
noncrit
ill
cancer
patient
howev
outcom
differ
report
cancer
patient
requir
mechan
ventil
interestingli
influenza
season
patient
febril
neutropenia
identifi
case
condit
usual
investig
scenario
howev
febril
neutropen
cancer
patient
increas
risk
develop
respiratori
distress
multiorgan
failur
therefor
screen
respiratori
virus
prompt
initi
oseltamivir
treatment
consid
patient
febril
neutropenia
indic
poor
prognost
respect
patient
outcom
neutropenia
durat
cohort
patient
less
seven
day
thu
prolong
viral
shed
might
correl
neutropenia
observ
persist
patient
studi
purpos
individu
viral
shed
continu
least
day
despit
use
oseltamivir
median
durat
viral
shed
popul
day
two
pediatr
patient
acut
lymphoblast
leukemia
show
even
longer
viru
secret
day
figur
tabl
although
difficult
determin
whether
viral
persist
due
cancer
per
se
acut
lung
injuri
mechan
ventil
influenza
shed
consid
last
long
disappear
seven
day
onset
day
oseltamivir
placebotr
group
respect
studi
aim
monitor
viru
shed
use
random
trial
appropri
control
outpati
hospit
immunocompromis
individu
yet
conduct
also
unabl
establish
agematch
control
without
immunosuppress
sinc
studi
conduct
peak
first
wave
pandem
brazil
compar
work
studi
shed
gener
hospit
immunocompromis
popul
tabl
summar
cohort
use
studi
whether
immunocompromis
underli
diseas
number
patient
analyz
viral
shed
studi
compar
maximum
period
shed
among
differ
popul
number
patient
secret
viru
seven
day
data
would
inform
relev
public
health
point
view
durat
quarantin
approxim
long
found
tabl
household
hong
kong
canada
maximum
period
shed
rang
day
period
differ
observ
militari
cadet
contain
phase
pandem
vietnam
tabl
regard
shed
among
infant
hien
et
al
show
children
five
nine
year
old
could
secret
viru
five
six
day
markedli
lower
observ
season
influenza
viru
compar
result
observ
higher
period
viral
shed
two
sevenyearold
patient
acut
lymphoblast
leukemia
tabl
figur
howev
singl
report
two
travel
franc
show
appar
immunocompet
individu
secret
viru
day
tabl
although
period
time
compar
time
frame
viru
secret
hospit
patient
china
work
studi
feluri
et
al
might
bias
small
size
cohort
tabl
influenzainfect
immunocompromis
individu
may
prolong
influenza
shed
howev
insight
necessari
better
comprehend
dynam
viru
individu
mora
et
al
show
individu
coinfect
viru
might
lead
outcom
differ
one
expect
immunocompet
subject
although
systemat
analysi
viral
shed
perform
similar
conclus
also
drawn
transplant
recipi
individu
whose
longest
period
viral
shed
exceed
day
tabl
studi
found
period
shed
similar
cdc
observ
leukemia
patient
tabl
although
small
size
cohort
immunocompromis
individu
includ
may
requir
conclus
mechanist
analysi
observ
may
stimul
systemat
studi
understand
gain
insight
factor
associ
prolong
shed
addit
might
give
insight
basic
studi
influenza
pathogenesi
result
highlight
need
closer
surveil
cancer
patient
infect
detect
first
neg
sampl
hypothes
followup
protocol
aim
monitor
persist
viral
shed
cancer
patient
may
relev
patient
submit
immunosuppress
therapi
day
week
prior
follow
infect
next
sought
determin
viral
evolut
prolong
shed
found
amino
acid
chang
persist
initi
symptom
day
thereaft
suggest
patient
viral
persist
rather
reinfect
addit
extra
amino
acid
chang
found
viral
ha
sequenc
month
onset
ill
suggest
continu
viral
evolut
although
mutat
found
strain
previous
describ
amino
acid
residu
chang
detect
studi
found
virus
throughout
world
without
signific
link
viral
pathogenesi
antigen
variat
influenza
virus
resist
antivir
drug
report
immunocompromis
patient
resist
might
associ
prolong
viral
shed
notabl
five
isol
two
patient
high
valu
neuraminidas
inhibitor
nai
na
activ
multiresist
nai
identifi
could
due
presenc
streptococcu
strain
found
throat
swab
tracheal
aspir
pyrosequenc
analys
sampl
high
valu
reveal
specimen
wildtyp
sensit
virus
result
reinforc
need
addit
genotyp
assay
confirm
identif
put
resist
strain
identifi
use
function
assay
addit
find
show
need
investig
sourc
na
activ
viru
isol
odd
valu
appar
paradox
prolong
viral
shed
without
antivir
resist
could
explain
either
inabl
immunocompromis
host
effect
clear
viru
ineffici
absorpt
drug
combin
clinic
molecular
virolog
data
result
might
contribut
discuss
adequ
durat
type
treatment
immunocompromis
patient
protract
cours
patient
use
parenter
system
inhal
antivir
also
investig
although
work
investig
uniqu
dynam
viru
infect
immunocompromis
host
caveat
must
note
investig
start
new
pandem
clinic
evalu
manag
protocol
chang
cours
studi
new
data
emerg
literatur
updat
recommend
pandem
reach
peak
south
america
establish
larger
divers
cohort
agematch
control
without
immunosuppress
becam
complex
thu
indepth
multivari
mechanist
clinic
analys
limit
moreov
recommend
monitor
viral
persist
avail
therefor
subset
sever
ill
patient
admit
icu
evalu
despit
import
connect
clinic
laboratori
inform
studi
reveal
continu
evolut
ha
sequenc
stabil
na
gene
sever
ill
patient
conclus
studi
provid
evid
sever
infect
associ
signific
morbid
mortal
cancer
patient
patient
viral
persist
without
emerg
antivir
resist
may
occur
clinic
cours
diseas
result
major
implic
clinic
manag
infect
infect
control
strategi
studi
may
provid
insight
shed
might
contribut
develop
new
guidelin
manag
cancer
patient
infect
ethic
committe
de
em
pesquisa
cep
http
wwwincagovbrconteudoviewasp
instituto
nacion
de
inca
rio
de
janeiro
brazil
head
dr
adriana
scheliga
approv
studi
protocol
waiv
need
inform
consent
prospect
cohort
studi
conduct
hospit
instituto
nacion
de
hciinca
rio
de
janeiro
brazil
juli
octob
hciinca
comprehens
cancer
center
primarili
popul
rio
de
janeiro
neighbor
state
present
studi
strictli
observ
everi
clinic
decis
discret
attend
physician
patient
definit
diagnosi
cancer
requir
hospit
admiss
reason
display
influenzalik
ill
evalu
patient
complet
remiss
cancer
five
year
consid
data
collect
use
standard
case
report
form
includ
demograph
data
clinic
present
comorbid
cancer
statu
use
immunosuppress
therapi
time
cours
acut
ill
need
intens
care
use
antivir
adjunct
therapi
advanc
life
support
inhospit
mortal
support
inform
si
patient
includ
fever
andor
respiratori
influenzalik
ill
confirm
influenza
diagnosi
least
one
three
assay
ifi
rrtpcr
cell
cultur
accord
case
definit
patient
treat
accord
brazilian
public
health
guidelin
nasopharyng
dacronswab
specimen
collect
patient
place
onto
transport
medium
hank
solut
uml
penicillin
streptomycin
initi
evalu
tracheal
aspir
also
obtain
patient
requir
tracheal
intub
patient
clinic
sampl
directli
test
panel
respiratori
virus
use
ifi
assay
influenza
respiratori
viru
panel
biotrin
mount
merrion
co
dublin
ireland
specimen
also
sent
brazilian
nation
influenza
center
iocfiocruz
confirm
use
rrtpcr
perform
accord
current
guidelin
whocdc
viral
shed
evalu
subset
patient
remain
mechan
ventil
longer
seven
day
patient
persist
hypoxemia
pulmonari
infiltr
patient
receiv
specif
number
sampl
number
append
first
sampl
subsequ
specimen
number
consecut
tabl
viral
secret
evalu
use
cell
cultur
rrtpcr
assay
neg
viru
isol
perform
madindarbi
canin
kidney
mdck
cell
andor
embryon
egg
see
text
tabl
function
antivir
assay
perform
use
nastar
kit
appli
biosystem
ca
accord
manufactur
instruct
rtpcr
protocol
sequenc
use
sanger
method
pyrosequenc
present
si
well
phylogenet
analysi
blood
sampl
routin
sent
bacteri
cultur
tracheal
aspir
patient
intub
standard
descript
statist
use
describ
studi
popul
continu
variabl
report
mean
standard
deviat
median
rang
appropri
univari
analysi
use
identifi
factor
associ
hospit
mortal
twosampl
ttest
chisquar
fisher
exact
test
also
use
twotail
p
valu
consid
statist
signific
